In a recent investigation we took a hard look at the cybersecurity practices of major direct-to-consumer DNA testing ...

Lilly confirmed it would buy a Boston-based clinical-stage company developing genetic medicines for cardiovascular disease.

Regeneron Pharmaceuticals took a modest hit as BDF Gestion reduced its stake by 11.5% in the first quarter, now holding $2.8 ...

Kiniksa Pharmaceuticals sees strong growth from Arcalyst, aided by Medicare redesign. Learn about 2025 sales outlook & ...

The 12-month price targets, analyzed by analysts, offer insights with an average target of $33.11, a high estimate of $68.00, ...

Pallas Capital Advisors jumped into the biotech game by purchasing $426,000 worth of Regeneron Pharmaceuticals shares during ...

De Meo plans to pursue challenges outside the automotive industry after five years leading the carmaker, with one report suggesting he is to become the new boss of Kering. The commercial and clinical ...

The S&P 500 rebounded in May, but some stocks crashed on company-specific concerns. While one healthcare giant withdrew its ...

Regeneron is backing away from buying the DNA-testing company after a nonprofit controlled by co-founder Wojcicki made a higher bid. The private-equity firm plans to bid against rival Advent ...

The co-founder of bankrupt genetic analysis company 23andMe won an auction for the firm’s assets, agreeing, along with a ...